Browsing: Novo

Eli Lilly(NYSE: LLY) and Novo Nordisk(NYSE: NVO) are currently the leaders in the weight loss market. Their medicines have proved highly effective and generate billions in annual sales. However, drugs such as Wegovy and Zepbound are intended to treat patients with common forms of obesity. A little-known biotech, Rhythm Pharmaceuticals(NASDAQ: RYTM), has developed medicines for…

Novo Nordisk has launched a late-stage trial testing smaller doses of its Wegovy pill, seeking the lowest maintenance dose that still keeps weight off. 

Novo Nordisk has begun a placebo-controlled trial in search of “the most optimal lower dose” for its oral GLP-1 medicine for weight loss

Novo Nordisk has begun a late-stage clinical trial to evaluate whether lower doses of its oral pill, Wegovy, can still deliver weight reduction, reported Reuters

LONDON, Aug 19 (Reuters) – Danish drugmaker Novo Nordisk is testing lower doses of its Wegovy pill in a new late-stage study to ‌find the lowest dose that still helps patients lose weight, according ‌to a U.S. government database of clinical trials

Novo Nordisk, a leading Danish pharmaceutical company, has embarked on a late-stage study to identify the minimal effective dose of its obesity drug, Wegovy. This strategic trial aims to retain market share in the competitive obesity sector, projected to be valued at over $100 billion annually by 2030

It’s already been a full commercial quarter since the April approval of Eli Lilly’s weight loss pill Foundayo—which means analysts now have around three months’ worth of sales data to see how the oral obesity battle is shaping up

The Danish pharmaceutical giant is quietly advancing a fresh weapon in the obesity wars. Novo Nordisk has registered a first-in-human Phase I trial for an undisclosed weight-loss candidate, NNC0721-8060, which will be tested against its own blockbuster semaglutide — the active ingredient behind Wegovy and Ozempic — across 142 participants. The move signals that management…

Novo Nordisk (ISIN DK0062498333) stock is trading in the mid-$40s per American depositary receipt after closing at $44.89 on August 17, 2026, leaving the shares down 11.8% year-to-date compared with a level of $50.88 at the start of 2026. Per recent market data, the stock was changing hands at $44.89 at 3:58 p.m. ET on…

Novo Nordisk has registered a first-in-human Phase I study of previously undisclosed obesity candidate NNC0721-8060, with a 142-participant program that will evaluate weight loss and include semaglutide alongside placebo despite the company keeping the asset’s target and modality under wraps